Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences
Sonoma Pharmaceuticals (Nasdaq:SNOA), a global healthcare leader developing Microcyn® technology based stabilized hypochlorous acid (HOCl) products, has announced its participation in two upcoming investor conferences:
1. Danisavage Financial Strategies Virtual 1x1 Investor Conference on October 24 at 2:00pm ET. CEO Amy Trombly and CFO Jerry Dvonch will be available for one-on-one meetings.
2. LD Micro Main Event XVII on October 29 at 1:30am PT at the Luxe Sunset Blvd Hotel in Los Angeles, CA. The presentation will be webcast live, and one-on-one meetings will be available on October 29-30, 2024.
These conferences provide opportunities for investors to learn more about Sonoma's wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care.
Sonoma Pharmaceuticals (Nasdaq:SNOA), leader globale nel settore sanitario che sviluppa prodotti a base di acido ipocloroso (HOCl) stabilizzati con la tecnologia Microcyn®, ha annunciato la sua partecipazione a due importanti conferenze per investitori imminenti:
1. Conferenza Virtuale 1x1 per Investitori di Danisavage Financial Strategies il 24 ottobre alle 14:00 ET. L'Amministratore Delegato Amy Trombly e il Direttore Finanziario Jerry Dvonch saranno disponibili per incontri individuali.
2. LD Micro Main Event XVII il 29 ottobre alle 1:30 PT presso il Luxe Sunset Blvd Hotel a Los Angeles, CA. La presentazione sarà trasmessa in diretta streaming, e saranno disponibili incontri individuali il 29 e 30 ottobre 2024.
Queste conferenze offrono l'opportunità agli investitori di conoscere meglio la vasta gamma di applicazioni di Sonoma, inclusi la cura delle ferite, la salute degli occhi, la salute orale e nasale, le condizioni dermatologiche, la podologia e la salute animale.
Sonoma Pharmaceuticals (Nasdaq:SNOA), líder mundial en atención médica que desarrolla productos a base de ácido hipocloroso (HOCl) estabilizado con tecnología Microcyn®, ha anunciado su participación en dos próximas conferencias para inversionistas:
1. Conferencia Virtual 1x1 para Inversionistas de Danisavage Financial Strategies el 24 de octubre a las 2:00 p.m. ET. La CEO Amy Trombly y el CFO Jerry Dvonch estarán disponibles para reuniones individuales.
2. LD Micro Main Event XVII el 29 de octubre a la 1:30 a.m. PT en el Luxe Sunset Blvd Hotel en Los Ángeles, CA. La presentación se transmitirá en vivo, y las reuniones individuales estarán disponibles el 29 y 30 de octubre de 2024.
Estas conferencias ofrecen a los inversionistas oportunidades para conocer más sobre la amplia gama de aplicaciones de Sonoma, incluyendo cuidado de heridas, salud ocular, cuidado oral y nasal, condiciones dermatológicas, podología y cuidado de la salud animal.
소노마 제약 (Nasdaq:SNOA)는 Microcyn® 기술을 기반으로 한 안정화된 하이포클로러스 산(HOCl) 제품을 개발하는 글로벌 헬스케어 리더로, 다가오는 두 개의 투자자 회의에 참여할 것이라고 발표했습니다:
1. 다니세이지 금융 전략 가상 1x1 투자자 회의가 10월 24일 오후 2시에 ET로 진행됩니다. CEO 에이미 트롬블리와 CFO 제리 드본치는 1대1 회의에 참석할 수 있습니다.
2. LD 마이크로 메인 이벤트 XVII가 10월 29일 오전 1시 30분 PT에 로스앤젤레스, CA의 Luxe Sunset Blvd 호텔에서 개최됩니다. 발표는 생중계되며, 2024년 10월 29-30일 사이에 1대1 회의가 가능합니다.
이번 회의는 투자자들에게 소노마의 다양한 응용 분야에 대해 알릴 기회를 제공합니다. 이에는 상처 치료, 안과, 구강 및 비강 치료, 피부 질환, 족부학 및 동물 건강 관리가 포함됩니다.
Sonoma Pharmaceuticals (Nasdaq:SNOA), un leader mondial de la santé développant des produits à base d'acide hypochloreux (HOCl) stabilisé grâce à la technologie Microcyn®, a annoncé sa participation à deux conférences pour investisseurs à venir :
1. Conférence Virtuelle 1x1 pour Investisseurs de Danisavage Financial Strategies le 24 octobre à 14h00 ET. La PDG Amy Trombly et le DAF Jerry Dvonch seront disponibles pour des réunions en tête-à-tête.
2. LD Micro Main Event XVII le 29 octobre à 1h30 PT au Luxe Sunset Blvd Hotel à Los Angeles, CA. La présentation sera diffusée en direct, et des réunions individuelles seront possibles les 29 et 30 octobre 2024.
Ces conférences offrent aux investisseurs l'opportunité d'en apprendre davantage sur la vaste gamme d'applications de Sonoma, notamment les soins des plaies, les soins des yeux, les soins buccaux et nasaux, les conditions dermatologiques, la podologie et les soins de santé animale.
Sonoma Pharmaceuticals (Nasdaq:SNOA), ein weltweit führendes Unternehmen im Gesundheitswesen, das Produkte auf Basis von stabilisiertem hypochloriger Säure (HOCl) mit der Microcyn® Technologie entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt:
1. Danisavage Financial Strategies Virtuelle 1x1 Investorenkonferenz am 24. Oktober um 14:00 Uhr ET. CEO Amy Trombly und CFO Jerry Dvonch stehen für Einzelgespräche zur Verfügung.
2. LD Micro Main Event XVII am 29. Oktober um 1:30 Uhr PT im Luxe Sunset Blvd Hotel in Los Angeles, CA. Die Präsentation wird live übertragen, und Einzelgespräche sind am 29. und 30. Oktober 2024 möglich.
Diese Konferenzen bieten den Investoren die Möglichkeit, mehr über die breite Palette von Anwendungen von Sonoma zu erfahren, einschließlich Wundversorgung, Augen-, Mund- und Nasenpflege, dermatologischen Erkrankungen, Podologie und tierärztlicher Versorgung.
- None.
- None.
BOULDER, CO / ACCESSWIRE / October 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced it will be presenting at two upcoming investor conferences.
Danisavage Financial Strategies Virtual 1x1 Investor Conference
Sonoma is scheduled to present on Thursday, October 24 at 2:00pm ET at the Danisavage Financial Strategies Virtual 1x1 Investor Conference. Amy Trombly, CEO, and Jerry Dvonch, CFO, will also be available for one-on-one meetings.
To view the presentation or receive additional information, please email rdanisavage@danisavage.com.
LD Micro Main Event XVII
Sonoma is scheduled to present in person and webcast live on October 29 at 1:30am PT at the Luxe Sunset Blvd Hotel in Los Angeles, CA. You can listen to the webcast at SNOA Investor Presentation Webcast. Amy Trombly, CEO, and Jerry Dvonch, CFO, will be available for one-on-one meetings to be held on October 29-30, 2024.
To receive additional information, register to attend, or schedule a one-on-one meeting, please email mary@ldmicro.com or meetings@ldmicro.com.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When is Sonoma Pharmaceuticals (SNOA) presenting at the Danisavage Financial Strategies conference?
What is the date and time of Sonoma Pharmaceuticals' (SNOA) presentation at LD Micro Main Event XVII?
Will Sonoma Pharmaceuticals (SNOA) offer one-on-one meetings at these investor conferences?
What technology does Sonoma Pharmaceuticals (SNOA) specialize in?
